APA (7th ed.) Citation

B, L., S, S., E, A., H, H., P, S., R, d. C., . . . R, Z. (1998). Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: Final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 16(3), 872. https://doi.org/10.1200/JCO.1998.16.3.872

Chicago Style (17th ed.) Citation

B, Löwenberg, et al. "Mitoxantrone Versus Daunorubicin in Induction-consolidation Chemotherapy--the Value of Low-dose Cytarabine for Maintenance of Remission, and an Assessment of Prognostic Factors in Acute Myeloid Leukemia in the Elderly: Final Report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 16, no. 3 (1998): 872. https://doi.org/10.1200/JCO.1998.16.3.872.

MLA (9th ed.) Citation

B, Löwenberg, et al. "Mitoxantrone Versus Daunorubicin in Induction-consolidation Chemotherapy--the Value of Low-dose Cytarabine for Maintenance of Remission, and an Assessment of Prognostic Factors in Acute Myeloid Leukemia in the Elderly: Final Report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 16, no. 3, 1998, p. 872, https://doi.org/10.1200/JCO.1998.16.3.872.